Zhang Liang, Cui Ling-Li, Yang Wen-He, Xue Fu-Shan, Zhu Zhi-Jun
Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Division of Liver Transplantation, Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Front Surg. 2022 Jul 27;9:939223. doi: 10.3389/fsurg.2022.939223. eCollection 2022.
Hepatic ischemia-reperfusion injury (HIRI) is largely unavoidable during liver transplantation (LT). Dexmedetomidine (DEX), an 2-adrenergic agonist, exerts a variety of organ-protective effects in pediatric populations. However, evidence remains relatively limited about its hepatoprotective effects in pediatric living-related LT.
A total of 121 pediatric patients undergoing living-related LT from June 2015 to December 2018 in our hospital were enrolled. They were classified into DEX or non-DEX groups according to whether an infusion of DEX was initiated from incision to the end of surgery. Primary outcomes were postoperative liver graft function and the severity of HIRI. Multivariate logistic regression and propensity score matching (PSM) analyses were performed to identify any association.
A 1:1 matching yielded 35 well-balanced pairs. Before matching, no significant difference was found in baseline characteristics between groups except for warm ischemia time, which was longer in the non-DEX group (44 [38-50] vs. 40 [37-44] min, = 0.017). After matching, the postoperative peak lactic dehydrogenase levels decreased significantly in the DEX group than in the non-DEX group (622 [516-909] vs. 970 [648-1,490] IU/L, = 0.002). Although there was no statistical significance, a tendency toward a decrease in moderate-to-extreme HIRI rate was noted in the DEX group compared to the non-DEX group (68.6% vs. 82.9%, = 0.163). Patients in the DEX group also received a significantly larger dosage of epinephrine as postreperfusion syndrome (PRS) treatment (0.28 [0.17-0.32] vs. 0.17 [0.06-0.30] µg/kg, = 0.010). However, there were no significant differences between groups in PRS and acute kidney injury incidences, mechanical ventilation duration, intensive care unit, and hospital lengths of stay. Multivariate analysis revealed a larger graft-to-recipient weight ratio (odds ratio [OR] 2.657, 95% confidence interval [CI], 1.132-6.239, = 0.025) and intraoperative DEX administration (OR 0.333, 95% CI, 0.130-0.851, = 0.022) to be independent predictors of moderate-to-extreme HIRI.
This study demonstrated that intraoperative DEX could potentially decrease the risk of HIRI but was associated with a significant increase in epinephrine requirement for PRS in pediatric living-related LT. Further studies, including randomized controlled studies, are warranted to provide more robust evidence.
肝缺血再灌注损伤(HIRI)在肝移植(LT)过程中很大程度上难以避免。右美托咪定(DEX)是一种α2肾上腺素能激动剂,在儿科人群中发挥多种器官保护作用。然而,关于其在小儿活体肝移植中的肝保护作用的证据仍然相对有限。
纳入2015年6月至2018年12月在我院接受活体肝移植的121例儿科患者。根据从切口至手术结束是否输注DEX,将他们分为DEX组或非DEX组。主要结局是术后移植肝功能和HIRI的严重程度。进行多因素逻辑回归和倾向评分匹配(PSM)分析以确定是否存在关联。
1:1匹配产生35对平衡良好的配对。匹配前,除热缺血时间外,两组间基线特征无显著差异,非DEX组热缺血时间更长(44 [38 - 50]分钟 vs. 40 [37 - 44]分钟,P = 0.017)。匹配后,DEX组术后乳酸脱氢酶峰值水平显著低于非DEX组(622 [516 - 909] IU/L vs. 970 [648 - 1490] IU/L,P = 0.002)。虽然无统计学意义,但与非DEX组相比,DEX组中重度至极重度HIRI发生率有下降趋势(68.6% vs. 82.9%,P = 0.163)。DEX组患者作为再灌注综合征(PRS)治疗使用的肾上腺素剂量也显著更大(0.28 [0.17 - 0.32] μg/kg vs. 0.17 [0.06 - 0.30] μg/kg,P = 0.010)。然而,两组在PRS和急性肾损伤发生率、机械通气时间、重症监护病房及住院时间方面无显著差异。多因素分析显示,更大的移植物与受体体重比(比值比[OR] 2.657,95%置信区间[CI],1.132 - 6.239,P = 0.025)和术中使用DEX(OR 0.333,95% CI,0.130 - 0.851,P = 0.022)是中重度至极重度HIRI的独立预测因素。
本研究表明,术中使用DEX可能会降低小儿活体肝移植中HIRI的风险,但与PRS治疗所需肾上腺素剂量显著增加有关。需要进一步研究,包括随机对照研究,以提供更有力的证据。